Investing in biomedical discoveries
LASCCO SA is a biomedical-technology development private company based in Geneva, Switzerland. The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.
LASCCO and Sepstone Diagnostics announce important milestone reached by Abionic in the development of the rapid PSP test for sepsis - 12/10/2016
Combioxin SA escalates to high dose in CAL02-001 trial in patients with severe pneumococcal pneumonia following IDMC's positive recommendation- 09/08/2016